ArticleNature communications2026
Vascular and lymphatic dysregulation via non-EndoMT Col2a1 signaling in bisphosphonate-related osteonecrosis of the jaw.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of antiresorptive therapy with poorly understood vascular mechanisms. Here, we integrate whole-organ tissue-clearing imaging, single-cell transcriptomics, and proteomics to construct a multimodal atlas of the mouse and human BRONJ mandibular microenvironment. We identify gross vascular and lymphatic rarefaction and four endothelial subtypes with aberrant Col2a1 upregulation. Fibroblasts and macrophages emerge as key endothelial interactors, highlighting dysregulation of the endothelium-matrix-immune axis. Unlike homeostatic Dmp1⁺/Tfap2a⁺ fibroblasts and Stab1⁺ macrophages, BRONJ lesions feature pathological Lrrc15⁺/Chad⁺ fibroblasts and Il6⁺ macrophages, driving ectopic chondrogenesis and inflammation. Mechanistically, the COL2A1-CD44 axis (EC-to-fibroblast/macrophage signaling) and COL2A1-SDC4 axis (EC-to-fibroblast signaling) are upregulated in BRONJ disease condition, while lineage tracing excludes EndoMT, implicating extracellular matrix remodeling. We functionally validate this axis via localized Col2a1 siRNA silencing and endothelial-specific genetic deletion. Cross-species validation in human mandibles confirms vascular-lymphatic dysregulation, inflammation, and chondrogenesis. Overall, we establish vascular and lymphatic dysregulation as a BRONJ hallmark and identify the COL2A1-CD44/SDC4 axis as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.